CAR

Century Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates

Retrieved on: 
Thursday, November 9, 2023
Research, Bristol Myers Squibb, CAR, Lymphoma, Neogene, Patent, IPSC, CD19, G&A, Inflammation, GAAP, MBA, Differentiable function, R, BMS, ASH, Pharming, Century, Research and development, Interim, Ink, Autoimmunity, Cancer, Investment, Therapy, Patient, Administration, Life insurance, Pharmaceutical industry, Management, Cryptocurrency

PHILADELPHIA, Nov. 09, 2023 (GLOBE NEWSWIRE) --  Century Therapeutics, Inc. (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today reported financial results and business highlights for the third quarter ended September 30, 2023.

Key Points: 
  • - Ended third quarter 2023 with cash, cash equivalents, and investments of $284.3 million; Cash runway into 2026 -
    PHILADELPHIA, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics , Inc. (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today reported financial results and business highlights for the third quarter ended September 30, 2023.
  • Greg Russotti, Interim Chief Executive Officer, Century Therapeutics added, “We continued to advance our Phase 1 ELiPSE-1 trial evaluating CNTY-101 in relapsed or refractory CD19 positive B-cell lymphomas.
  • He brings to Century over 20 years of broad-ranging global leadership experience across the healthcare industry, most recently serving as Chief Operating Officer at Neogene Therapeutics.
  • Cash Position: Cash, cash equivalents, and investments were $284.3 million as of September 30, 2023, as compared to $367.4 million as of December 31, 2022.

Cabaletta Bio Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, November 9, 2023
SLE, GMG, FDA, Systemic scleroderma, Research, CAR, CART, Report, American College, IND, Syndrome, Cyclophosphamide, MPV, MuSK protein, Dermatomyositis, Food, Nidec ASI, Myositis, Oxford, CD19, Molecular Therapy, Pemphigus, Good manufacturing practice, MG, Lupus, Conference, University, DM, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Maintenance, American College of Rheumatology, Development, Wuxi, San Diego Convention Center, Disease, Scleroderma, Immunoglobulin therapy, GMP, Autoimmunity, Investment, Patient, ACR, Investigational New Drug, Pharmaceutical industry, Vaccine, Nightclub, Cryptocurrency, Cabaletta, Limited

PHILADELPHIA, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today reported financial results for the third quarter ended September 30, 2023, and provided a business update.

Key Points: 
  • In November 2023, Cabaletta announced the Company’s fourth IND application for CABA-201 was cleared by the FDA for a Phase 1/2 study in patients with generalized myasthenia gravis (gMG).
  • Cabaletta will present new preclinical data for CABA-201 in a poster presentation and Cabaletta Bio Scientific Advisory Board members Carl June, M.D., and Georg Schett, M.D.
  • Cabaletta plans to participate in the following upcoming investor conferences:
    Stifel 2023 Healthcare Conference, which is being held from November 14-15, 2023 in New York, NY.
  • As of September 30, 2023, Cabaletta had cash, cash equivalents and short-term investments of $164.4 million, compared to $106.5 million as of December 31, 2022.

Celyad Oncology reports third quarter 2023 financial results and recent business highlights

Retrieved on: 
Thursday, November 9, 2023
CD95, CAR, NKG2D, 2023 International Conference on Climate Resilient Pakistan, RNA, Graft-versus-host disease, Public expenditure, CD19, ICLE, Conference, PD-1, Autophagy, Research, Mont-Saint-Guibert, Nucleic acid, SITC, Immunotherapy, Intrinsic termination, MicroRNA, Fortification, Dumont, B-ALL, Gene, Society, Anti-CD19 immunotoxin, PSMA, Patient, BCMA, Lymphocyte, Vaccine, Bank, Medical device, Euronext

“Celyad Oncology team is resolutely dedicated to harnessing our expertise, extensive know-how, and valuable intellectual property portfolio to address the existing challenges within CAR T-cell therapies.

Key Points: 
  • “Celyad Oncology team is resolutely dedicated to harnessing our expertise, extensive know-how, and valuable intellectual property portfolio to address the existing challenges within CAR T-cell therapies.
  • Celyad Oncology has relocated from September 25, 2023 into a new research facility which fits better its current needs after the strategic shift.
  • The Company remains headquartered at the Axis Parc, Mont-Saint-Guibert, Belgium but with its new business location at Dumont 9.
  • Net cash burn during the third quarter of 2023 amounted to €2.7 million, in line with expectations.

U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Retrieved on: 
Thursday, November 9, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, FDA, Clinical Trials, BMY, Bristol Myers Squibb, CAR, NYSE, PDUFA, Food, American Society of Clinical Oncology, SLL, Trial of the century, Prescription Drug User Fee Act, Head, Chronic lymphocytic leukemia, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Society, Lymphocytosis, Priority review, CLL, Annual general meeting, Patient, ASCO, Pharmaceutical industry, Hematology, Lisocabtagene maraleucel

The FDA has granted the application Priority Review and assigned a Prescription Drug User Fee Act (PDUFA) goal date of March 14, 2024.

Key Points: 
  • The FDA has granted the application Priority Review and assigned a Prescription Drug User Fee Act (PDUFA) goal date of March 14, 2024.
  • Priority Review designation underscores the high unmet need and the significant advancement Breyanzi may offer this patient population for which there is no standard of care and limited treatment options.
  • “This FDA acceptance brings us one step closer to offering these patients, for the first time, a personalized, T-cell based treatment option.
  • TRANSCEND CLL 004 is the first pivotal multicenter study to show clinical benefit with a CD19-directed CAR T cell therapy in patients with relapsed or refractory CLL after progression following treatment with a BTKi and BCL2i.

Sana Biotechnology Reports Third Quarter 2023 Financial Results and Business Updates

Retrieved on: 
Wednesday, November 8, 2023
Stem cell, Research, Insurance, CAR, Lymphoma, Patent, Leukemia, Bone marrow, Contingency, HIP, CTA, GAAP, SANA, Development, ASH, Biotechnology, Research and development, Transplant, Depreciation, Lymphoid leukemia, IST, Patient, Administration, Immunosuppression, Letter, State Administrative Expenses, Vaccine, Pharmaceutical industry, Commercial property, Cryptocurrency, Reinsurance, IND

Enrollment in the ARDENT Phase 1 study continues, and initial clinical data are expected in 2023 and more robust data expected in 2024.

Key Points: 
  • Enrollment in the ARDENT Phase 1 study continues, and initial clinical data are expected in 2023 and more robust data expected in 2024.
  • Initial HIP proof of concept data are expected in 2023 and 2024.
  • Sana is developing SC451, a hypoimmune-modified stem-cell derived pancreatic islet cell therapy for patients with type 1 diabetes.
  • A discussion of non-GAAP measures, including a reconciliation of GAAP and non-GAAP measures, is presented below under “Non-GAAP Financial Measures.”

Fate Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates

Retrieved on: 
Wednesday, November 8, 2023
Food, Multiple myeloma, CXCR2, Enrollment, B-cell lymphoma, Lupus, SITC, Cetuximab, Annual general meeting, Rituximab, SLE, CAR, Hyperbaric treatment schedules, GAAP, Graft-versus-host disease, Safety, Cancer, Therapy, Ono Pharmaceutical, Investment, Patient, IPSC, Society for Immunotherapy of Cancer, Chronic lymphocytic leukemia, Research, Immunotherapy, TRAC, CD16, NK, Clinical trial, Multiplexing, BCL, Acute leukemia, CRS, Cell, FDA, Trastuzumab, IND, ONO, ADR, HER2, Neoplasm, Protocol, Lupus Research Alliance, Destiny, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Pharmacokinetics, Tumor microenvironment, BCMA, Vaccine, Pharmaceutical industry, Autoimmunity

SAN DIEGO, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today reported business highlights and financial results for the third quarter ended September 30, 2023.

Key Points: 
  • FT522 is the Company’s off-the-shelf, multiplexed-engineered natural killer (NK) cell product candidate that incorporates five synthetic controls of cell function.
  • In addition, as of September 30, 2023, cash receivables from the Company’s collaboration with ONO were $1.5 million.
  • Shares Outstanding: Common shares outstanding were 98.6 million, and preferred shares outstanding were 2.8 million, as of September 30, 2023.
  • ET to review financial and operating results for the quarter ended September 30, 2023.

Adicet Reports Third Quarter 2023 Financial Results and Provides Business Updates

Retrieved on: 
Wednesday, November 8, 2023
Science, Stem Cells, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, CAR, Trial of the century, IND, Food, Bio, CD70, Renal cell carcinoma, International Conference on Afghanistan, London (2010), CD20, Society for Immunotherapy of Cancer, Tropism, TGF, Conference, CDMO, Regulation of tobacco by the U.S. Food and Drug Administration, Prostate cancer, R, Engineering, Poster, Goodwill, SITC, Immunotherapy, MCL, Research and development, Annual general meeting, Probability, ACET, Tumor microenvironment, Epitope, NHL, Society, Cancer, PSMA, Patient, Administration, Prognosis, Prostate, CD27, Pharmaceutical industry, Cryptocurrency

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today reported financial results and operational highlights for the third quarter ended September 30, 2023.

Key Points: 
  • Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today reported financial results and operational highlights for the third quarter ended September 30, 2023.
  • In October 2023, Adicet presented new preclinical data building on the potential of Adicet’s allogeneic gamma delta platform as a promising approach to target prostate cancer.
  • Financial Results for Third Quarter 2023:
    Research and Development (R&D) Expenses: R&D expenses were $26.2 million for the three months ended September 30, 2023, compared to $16.6 million during the same period in 2022.
  • Cash Position: Cash and cash equivalents were $183.3 million as of September 30, 2023, compared to $257.7 million as of December 31, 2022.

BRI's Financial Performance Draws Analysts' Recommendations for its Shares

Retrieved on: 
Thursday, November 9, 2023
ROA, Yoy, CAR, MSME, US, Government, Santana's El Nino, Pressure, IDX, Projection, Multimedia, ROI, Growth, BBRI, GGM, CGS, Price, BRI, DuPont, IDR, Chartered Financial Analyst, Security (finance), Bank

(IDX: BBRI)'s financial performance in Q3 2023 has ignited recommendations among analysts, who now advise 'buy' or 'hold' due to promising performance in the microsegment sector.

Key Points: 
  • (IDX: BBRI)'s financial performance in Q3 2023 has ignited recommendations among analysts, who now advise 'buy' or 'hold' due to promising performance in the microsegment sector.
  • PT UBS Sekuritas Indonesia's report raises BRI's target price to IDR 6,925, a 2-3% increase from their previous projection of IDR 6,700.
  • Furthermore, BNI Sekuritas targets BRI's price at IDR 6,000, in line with its current 1-year Price-to-Book Value of 2.3x, matching its 5-year average.
  • Despite asset quality challenges in Q3-2023 for mass-market-focused financial institutions, Q4 improvements propelled by election-related funding are expected.

ImmPACT Bio Recognized in BioSpace's 2024 Best Places to Work

Retrieved on: 
Wednesday, November 8, 2023
Culture, CAR, Cancer, News, Organization, The Last Best Place, Vaccine

LOS ANGELES, Nov. 8, 2023 /PRNewswire/ -- ImmPACT Bio USA, Inc. ("ImmPACT Bio"), a clinical-stage company developing transformative logic-gate-based chimeric antigen receptor (CAR) T-cell therapies for treating cancer and autoimmune diseases, today announced it has been named on the BioSpace 2024 Best Places to Work small employer list.

Key Points: 
  • LOS ANGELES, Nov. 8, 2023 /PRNewswire/ -- ImmPACT Bio USA, Inc. ("ImmPACT Bio"), a clinical-stage company developing transformative logic-gate-based chimeric antigen receptor (CAR) T-cell therapies for treating cancer and autoimmune diseases, today announced it has been named on the BioSpace 2024 Best Places to Work small employer list.
  • "We are honored to be recognized as part of the BioSpace 2024 Best Places to Work list, highlighting our commitment to fostering a collaborative and fulfilling culture at ImmPACT Bio," said Sumant Ramachandra, M.D., Ph.D., chief executive officer of ImmPACT Bio.
  • The 2024 BioSpace Best Places to Work list is made up of 60 U.S. companies that are recognized as the most sought after in the industry by the life sciences community.
  • ImmPACT Bio was recognized as one of 30 companies within the small company category.

Invert and The Earth Lab Announce Partnership to Advance Critical Nature-Based Projects in Mexico

Retrieved on: 
Wednesday, November 8, 2023
CAR, MRV, Yucatán Peninsula, Carbon, Organization, Partnership, Agriculture, Renewable energy, Inverse

The terms of the agreement cover investment and development of five regional projects on Ejido land, traditional land collectively owned and worked on by local communities.

Key Points: 
  • The terms of the agreement cover investment and development of five regional projects on Ejido land, traditional land collectively owned and worked on by local communities.
  • The nature-based projects will issue removal-focused Climate Reserve Tonnes, the unit of offset credits used by CAR.
  • "This is an extremely exciting opportunity to make a meaningful environmental and social impact that will benefit generations," said Andre Fernandez, co-CEO at Invert.
  • "Our partnership with Invert mirrors the growing industry sentiment and preference for high-quality carbon projects that protect nature while supporting the local community," said Jorge Calderon, CEO at The Earth Lab.